I van O (@onco_uroloog) 's Twitter Profile
I van O

@onco_uroloog

Not using X anymore, after so many years since it’s no longer compatible with my values

ID: 800864275

calendar_today03-09-2012 17:39:15

5,5K Tweet

1,1K Followers

1,1K Following

Timothy Daskivich (@timdaskivich) 's Twitter Profile Photo

How do we actually communicate risks of cancer and other cause death in prostate cancer consults? Turns out we fail to quantify cancer mortality, life expectancy, and survival benefit with treatment in 34% , 31%, and 71% of consults! buff.ly/3wrRhMJ

Melvin LK CHUA | FRCR, PhD, FASCO (@drmlchua) 's Twitter Profile Photo

Glad to see that our modest single arm phase 2 NEAR trial of neoadjuvant APA was cited as the top stories published in Prostate Cancer and Prostatic Diseases in 2022! Kudos to the team for pushing this through 💪🏻 JanssenUS Suneel Mundle Kae Jack Tay Ravindran Kanesvaran Joe Yeong nature.com/articles/s4139…

Glad to see that our modest single arm phase 2 NEAR trial of neoadjuvant APA was cited as the top stories published in <a href="/pcan_journal/">Prostate Cancer and Prostatic Diseases</a> in 2022!
Kudos to the team for pushing this through 💪🏻 <a href="/JanssenUS/">JanssenUS</a> <a href="/MundleSuneel/">Suneel Mundle</a> <a href="/KaeJackTay/">Kae Jack Tay</a> <a href="/ravikanesvaran/">Ravindran Kanesvaran</a> <a href="/JoeYeong/">Joe Yeong</a> 

nature.com/articles/s4139…
Prostate Cancer and Prostatic Diseases (@pcan_journal) 's Twitter Profile Photo

Our UCSF prostate cancer cohort shows that men who develop a detectable serum PSA >6 months after surgery may still have excellent long-term outcomes: rb.gy/vxhyls @JSzymaniakMD Cosimo De Nunzio

UroToday.com (@urotoday) 's Twitter Profile Photo

Patients with HR localized disease, M0 on conventional imaging but one bone lesion on PSMA PET/CT: arguments for a surgical approach +/- radiotherapy +/- systemic treatment. Presented by tombal @UCLouvain_be. #EAU23 Zach Klaassen > bit.ly/42bZqUm I van O

Patients with HR localized disease, M0 on conventional imaging but one bone lesion on PSMA PET/CT: arguments for a surgical approach +/- radiotherapy +/- systemic treatment. Presented by <a href="/BertrandTOMBAL/">tombal</a> @UCLouvain_be. #EAU23 <a href="/zklaassen_md/">Zach Klaassen</a> &gt; bit.ly/42bZqUm <a href="/onco_uroloog/">I van O</a>
Alastair Lamb (@lambalastair) 's Twitter Profile Photo

Jonathan O'Brien & Declan Murphy deliver one of highest quality videos of #EAU23 with slick, professional production values. This is how all videos should be put together! If only rest of our community had skills of this group. Key message: RP is safe/feasible after #Lutectomy

<a href="/JonathanSOBrien/">Jonathan O'Brien</a> &amp; <a href="/declangmurphy/">Declan Murphy</a> deliver one of highest quality videos of #EAU23 with slick, professional production values. This is how all videos should be put together! If only rest of our community had skills of this group.

Key message: RP is safe/feasible after #Lutectomy
European Association of Urology (EAU) (@uroweb) 's Twitter Profile Photo

🆕 During active surveillance, perform MRI and repeat biopsy if PSA is rising (PSA-doubling time < 3 years). #EAUGuidelines #ProstateCancer uroweb.org/guidelines/pro…

Prostate Cancer and Prostatic Diseases (@pcan_journal) 's Twitter Profile Photo

Meet the Editorial Board: Luca Cindolo expert in BPH/LUTS and minimally invasive surgery. Thanks for the great support to the journal! Luca Cindolo #editorial #pcsm #team #urosome

European Association of Urology (EAU) (@uroweb) 's Twitter Profile Photo

In pN0 patients with ISUP grade group 4–5 and pT3 ± positive margins, offer adjuvant intensity-modulated radiation therapy/volumetric modulated arc therapy plus image-guided radiation therapy. #EAUguidelines #ProstateCancer uroweb.org/guidelines/pro…

Alex Wyatt (@researchwyatt) 's Twitter Profile Photo

In our new paper in Clinical Cancer Research: plasma ctDNA% in pts with mCRPC after 4 wks of abi/enza tx inform on subsequent duration of response (outperforming clinical variables). Can on-treatment ctDNA changes guide an early treatment switch or intensification? aacrjournals.org/clincancerres/…

In our new paper in <a href="/CCR_AACR/">Clinical Cancer Research</a>: plasma ctDNA% in pts with mCRPC after 4 wks of abi/enza tx inform on subsequent duration of response (outperforming clinical variables). Can on-treatment ctDNA changes guide an early treatment switch or intensification? aacrjournals.org/clincancerres/…
Alex Wyatt (@researchwyatt) 's Twitter Profile Photo

This study was led by two top Dutch trainees: Drs. Sofie Tolmeijer & Emmy Boerrigter, as part of a long-standing collaboration with Profs Niven Mehra and Nielka van Erp (RadboudUMC) and ably supported by several members of my lab Vancouver Prostate Centre 👏

European Association of Urology (EAU) (@uroweb) 's Twitter Profile Photo

🆕 At the start of ADT offer luteinising hormone-releasing hormone antagonists or orchiectomy to patients with impending clinical complications, like spinal cord compression or bladder outlet obstruction. #ProstateCancer #EAUguidelines uroweb.org/guidelines/pro…

European Association of Urology (EAU) (@uroweb) 's Twitter Profile Photo

Discuss testis-sparing surgery with frozen section examination in patients with a high likelihood of having a benign testicular tumour which are suitable for enucleation. #EAUguidelines #TesticularCancer uroweb.org/guidelines/tes…